Detalhe da pesquisa
1.
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing.
Cytotherapy
; 26(3): 266-275, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231165
2.
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.
Br J Cancer
; 126(2): 174-186, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34621045
3.
Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity.
Nucleic Acids Res
; 48(4): 1800-1810, 2020 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31930333
4.
Metastasis: complexity thwarts precision targeting.
Br J Cancer
; 125(8): 1033-1035, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34226682
5.
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
Br J Cancer
; 124(1): 191-206, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33257837
6.
ESR1 mutations in breast cancer.
Cancer
; 125(21): 3714-3728, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31318440
7.
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Breast Cancer Res Treat
; 167(3): 731-740, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29110152
8.
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Breast Cancer Res Treat
; 157(2): 253-265, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27178332
9.
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.
Breast Cancer Res Treat
; 158(3): 441-54, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27393618
10.
Role of MTA2 in human cancer.
Cancer Metastasis Rev
; 33(4): 921-8, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25394532
11.
Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Breast Cancer Res Treat
; 154(2): 225-37, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26487496
12.
Targeting thyroid hormone receptor beta in triple-negative breast cancer.
Breast Cancer Res Treat
; 150(3): 535-45, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25820519
13.
Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight.
Breast Cancer Res Treat
; 144(1): 11-9, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24487689
14.
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Breast Cancer Res Treat
; 147(3): 473-85, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25178514
15.
Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Breast Cancer Res Treat
; 146(2): 273-85, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24928526
16.
Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.
Cancer Res
; 84(2): 291-304, 2024 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37906431
17.
PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Mol Cancer Ther
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38781103
18.
Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer.
Breast Cancer Res Treat
; 141(3): 375-384, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24077732
19.
Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.
Breast Cancer Res
; 14(3): R95, 2012 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-22697792
20.
Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Breast Cancer Res Treat
; 163(3): 639-640, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28439737